Full Text Available
Note: Clicking the button above will open the full text document at the original institutional repository in a new window.
Balancing the complex interplay between type 2 immunity‐targeting biologics and autoimmune phenomena in real‐world practice
Saved in:
| Published in: | Rheumatology & Autoimmunity |
|---|---|
| Format: | Online Article RSS Article |
| Published: |
2026
|
| Subjects: | |
| Tags: |
No Tags, Be the first to tag this record!
|
Similar Items: Balancing the complex interplay between type 2 immunity‐targeting biologics and autoimmune phenomena in real‐world practice
- Association of autoimmune diseases with biologic agents targeting type 2 immunity: An observational study using a claims database
- Epstein‐Barr virus as a driver of lupus: Rethinking triggers in autoimmunity
- Management of interstitial lung disease in systemic autoimmune rheumatic diseases: a survey of rheumatologists and pulmonologists
- Golimumab for the Treatment of Rheumatoid Arthritis: A Narrative Review of Pivotal Randomized Trials and Real-World Studies
- Impact of biological/targeted versus conventional synthetic disease‐modifying antirheumatic drugs on patient‐reported outcomes in rheumatoid arthritis
- Comparative Effectiveness of Upadacitinib vs. Other JAK Inhibitors in Patients With Rheumatoid Arthritis in a Global Real-World Setting